Insider trading

Period: 120 months Stock: GNLX + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

122 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

122 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

122 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

122 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
122 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
122 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

122 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
19 Sep 2023
Szalay Aladar 10% owner
Sold at will 2×
$850.94K 32,167 at 26.45
100%
Sold half or more
18 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$705.65K 30,292 at 23.29
85.8%
Sold half or more
18 Sep 2023
Thomas John Director
Sold at will
$83.32K 3,334 at 24.99
0.7%
Not planned
15 Sep 2023
Yu Yong VP, Clinical Trial Operations
Sold at will 2×
$227.63K 10,400 at 21.89
8.9%
Not planned
15 Sep 2023
Thomas John Director
Sold at will 2×
$73.00K 3,333 at 21.90
0.7%
Not planned
14 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$557.81K 25,276 at 22.07
41.7%
Not planned
13 Sep 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$629.93K 29,800 at 21.14
21.9%
Not planned
13 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$408.09K 19,032 at 21.44
23.9%
Not planned
13 Sep 2023
Smither John W Director
Sold at will
$18.70K 900 at 20.78
11.5%
Not planned
12 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$451.17K 20,265 at 22.26
20.3%
Not planned
11 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$718.70K 32,351 at 22.22
24.5%
Not planned
8 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 3×
$575.33K 24,831 at 23.17
15.8%
Not planned
7 Sep 2023
Szalay Aladar 10% owner · indirect
Sold at will 2×
$303.27K 12,446 at 24.37
7.3%
Not planned
30 Aug 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$489.06K 19,800 at 24.70
12.7%
Not planned
18 Aug 2023
Zindrick Thomas President and CEO
Sold at will
$198.12K 8,349 at 23.73
36.3%
Not planned
18 Aug 2023
Cappello Joseph VP, Pharmaceutical Development
Sold at will
$77.48K 3,265 at 23.73
36.3%
Not planned
18 Aug 2023
Yu Yong VP, Clinical Trial Operations
Sold at will
$77.48K 3,265 at 23.73
2.1%
Not planned
18 Aug 2023
Samuelson Doug Chief Financial Officer
Sold at will
$30.78K 1,297 at 23.73
36.0%
Not planned
18 Aug 2023
Smalling Ralph Head of Regulatory
Sold at will
$22.19K 935 at 23.73
31.2%
Not planned
18 Aug 2023
Jewett Caroline Head of Quality
Sold at will
$12.22K 515 at 23.73
31.2%
Not planned
18 Aug 2023
Ryder Sean General Counsel
Sold at will
$7.78K 328 at 23.73
36.4%
Not planned
26 Jan 2023
Zhang Qian Associate VP, Research · indirect
Bought
$1.25K 200 at 6.25
opened
First buy on file
Showing 101–122 of 122. ← Newer Page 3 of 3